Reported 1 day ago
H.C. Wainwright has upgraded Vor Biopharma Inc. (VOR) to a Buy rating, setting a price target of $3. The upgrade, announced by analyst Swayampakula Ramakanth, is based on the company’s growth potential and strategic agreements, including a recent licensing deal for telitacicept outside Greater China. This therapy has shown clinical promise and received approvals in various conditions, strengthening Vor's financial position through upfront and milestone payments.
Source: YAHOO